Clinical Trial Update: Post Marketing Survey of Vesicare in Japan

View source ↗

Summary

A post-marketing survey of Vesicare (solifenacin) conducted in Japan has completed, evaluating safety and usage in patients with overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Vesicare (solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Overactive Bladder | Status: COMPLETED